Cowen Starts Voyager Therapeutics (VYGR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
December 9, 2015 9:55 AM ESTChardan Capital Markets initiated coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Sell rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $30.11 yesterday.
... MoreWedbush Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 7:42 AM ESTWedbush initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten highlighted:
Pioneering AAV-based gene therapy for serious diseases of the central nervous system (CNS). VYGR has selected a number of CNS diseases with validated, specific gene targets that are amenable to AAV gene therapy. The CNS represents an ideal site for gene therapy due to its immune privilege status and terminally-differentiated cells that allow long-term transgene... MorePiper Jaffray Starts Voyager Therapeutics (VYGR) at Overweight
December 7, 2015 6:35 AM ESTPiper Jaffray initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating and a price target of $47.00.
Analyst Joshua E. Schimmer commented, "We are initiating coverage of VYGR with an OW rating and $47 PT based on a DCF analysis through 2022 with an 11%... More
